ALGOTX
14.3.2023 08:02:19 CET | Business Wire | Press release
European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secured an additional 1M€ in non-dilutive financing. The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
Bervin Bouani, Investment Director at Turenne Capital, commented: “We are very proud to lead this strategic financing round to support AlgoTx to continue the clinical development of ATX01 lead candidate that has the potential to significantly improve the lives of patients with neuropathic pain. We look forward to working with Stéphane and his outstanding team to transform AlgoTx into a global pain player.”
Following the demonstration of ATX01’s early clinical safety and low systemic passage in Phase 1, the Phase 2 “ACT” study will now assess ATX01’s ability to reduce pain in adult CIPN patients – a program granted “fast-track” designation by FDA. In parallel, the Phase 2 “EASE” study will explore ATX01’s efficacy in the debilitating pain of erythromelalgia, a program for which ATX01 was granted “Orphan Disease Designation” in the US and Europe.
Stéphane Thiroloix, Founder & CEO of AlgoTx, says: “It is incredibly exciting to start the efficacy trials of ATX01, supported by such a high-profile syndicate of investors. We look forward to enrolling patients in our studies any day now.”
Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. It affects over two million patients in the US and Europe and represents a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.
« We are very pleased to support the AlgoTx team in the development of ATX01, driven by our belief in its significant impact in the treatment of CIPN and other neuropathic pain. AlgoTx can truly transform the lives of patients suffering from these conditions », says Pauline de Breteuil Senior Partner UI Investissement / FCPI Majycc Innovation Santé.
About AlgoTx
AlgoTx develops novel treatments for complex pain, with lead program ATX01 in Phase 2 in chemotherapy-induced peripheral neuropathy (NCT05593614) and erythromelalgia. More information at www.algotx.com
ACT study : ATX01 for the pain of ChemoTherapy, (NCT05593614). EASE study : Efficacy of ATX01 / Study in Erythromelalgia.
ABOUT TURENNE GROUP/RELYENS INNOVATION SANTÉ
Launched in 2014, Relyens Innovation Santé is is an evergreen venture capital vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social and medical players. Relyens is the leading French player in medical civil liability. Advised by Turenne Santé (Health Division of Turenne Group), Relyens Innovation Santé's mission is to support the growth and development phases of innovative companies in the health sector.
Turenne Group, one of the leading private equity companies in France, has been supporting entrepreneurs for 23 years in their company’s innovation, development and transfer projects. As an independent player, the Group has assets of €1.4 billion under management. Its teams, made up of 68 professionals, including 52 investors, based in Paris, Lille (Nord Capital Partenaires), Lyon, Bordeaux, Marseille, Nice and Metz, support 290 business leaders, particularly in the healthcare, hospitality, innovation, BtoB services, and in the digital and impact sectors. With more than €300m, our healthcare team (Turenne Santé) invests across the entire value creation chain for healthcare companies through various investment approaches.
For more information: www.relyens.eu/fr / www.turennecapital.com
About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Investment Fund and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
For more information, please visit: www.bpifrance.com – Follow us on Twitter : @bpifrance - @BpifrancePresse
About Omnes
Omnes is a leading Paris-based European investor in private equity and infrastructure. With more than €5 billion in assets under management, Omnes provides companies with the equity capital they need to grow through its four core businesses: Venture Capital, Buyout & Growth Capital, Infrastructure and Co-Investment. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Themis Bioscience, Biovex, arGEN-X, Novaled and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. The company is also a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com
About UI Investissement
UI Investissement is an independent, specialized company in the development of unlisted French companies with €1.5 billion under management. For over 50 years, UI Investissement has been committed to work alongside the managers of growing SMEs and STIs to help them emerge as economically and sustainably successful businesses through its focus on three areas: health, agro-business, and business services.
With its expertise, UI Investissement provides support to companies in the health sector at all stages of their development and plays a central role in the ecosystem. It is through the Majycc Innovation Santé fund that UI Investissement supports entrepreneurs who aim to be the architects of tomorrow's health. The roots of Majycc Innovation Santé are deeply connected to the DNA of several private clinic groups, nursing home groups, and mutual health insurance companies, representing entrepreneurship, health and human values, respect for corporate culture, and the projects of the individuals who build them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bentley Systems Announces 2026 Year in Infrastructure Event and YII Awards Honoring the World’s Most Innovative Use of Infrastructure Engineering Software18.3.2026 13:00:00 CET | Press release
Awards build on a two-decade legacy of recognized innovation, setting the benchmark for excellence across the world’s most critical infrastructure assetsCall for nominations now open; submissions will be accepted through May 3, 2026 Bentley Systems, Incorporated (NASDAQ: BSY), the infrastructure engineering software company, today announced the opening of submissions for the Year in Infrastructure event and YII Awards program, which recognizes digital innovation in how infrastructure is designed, built, and operated using Bentley software. Submissions will be accepted through May 3, at 11:59 p.m. EDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318559906/en/ Bentley Systems announced the opening of submissions for the Year in Infrastructure event and YII Awards program, which recognizes digital innovation in how infrastructure is designed, built, and operated using Bentley software. Submissions will be accepted through
Veracode Expands Industry-Leading Fix with AI-Powered SCA Remediation to Combat Software Supply Chain Risk18.3.2026 13:00:00 CET | Press release
New Capability Automates Open-Source Vulnerability Remediation as Software Supply Chain Attacks Surge RSA Conference (booth #435)--Veracode, the global leader in application risk management, today announced Veracode Fix for Software Composition Analysis (SCA), an AI-powered solution to address software supply chain risk. The enhanced automated remediation engine—the next evolution of Veracode’s industry-leading Fix solution—enables organizations to detect and remediate open-source vulnerabilities easily, before code reaches production. Designed to integrate seamlessly into existing developer workflows, it delivers third-party updates and first-party code refactoring without breaking builds or disrupting development. In 2025, software supply chain breaches accounted for 30 percent of external attacks. Meanwhile Veracode’s 2026 State of Software Security (SoSS) Report revealed 82 percent of organizations struggle with escalating security debt, largely due to open-source dependencies. Ver
Armis Appoints Simon Mouyal as Chief Marketing Officer18.3.2026 13:00:00 CET | Press release
Strategic marketing executive to accelerate adoption of Armis Centrix™ in the agentic AI era and extend the company’s category leadership in cyber exposure management and CPS security Armis, the cyber exposure management & security company, today announced the appointment of Simon Mouyal as Chief Marketing Officer. In this role, Mouyal will oversee Armis’ global marketing strategy and execution to accelerate category leadership and demand for Armis Centrix™, the Armis Cyber Exposure Management Platform. During the next phase of Armis’ expansion, he will scale the global marketing organization and help further drive the company’s rapid growth and market penetration. “As we enter our next chapter of hyper-growth, I'm thrilled to have Simon joining our leadership team,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Simon will be instrumental in modernizing our global marketing engine and solidifying Armis as the definitive leader in cyber exposure management. He's a category creator
Americhem Appoints Kilian Lamprecht as Vice President of Mergers & Acquisitions to Accelerate Strategic Growth18.3.2026 12:00:00 CET | Press release
Americhem, a global leader in polymer solutions, today announced that Kilian Lamprecht has joined the company as Vice President of Mergers & Acquisitions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317304976/en/ Kilian Lamprecht, Vice President of Mergers & Acquisitions, Americhem Lamprecht brings extensive experience in corporate development and integration within global industrial and technology organizations. He will work closely with Americhem’s executive leadership team and investment partner PPC to identify and execute strategic acquisitions, partnerships and portfolio investments that expand the company’s capabilities, product portfolio and geographic reach. “Americhem has a long history of disciplined growth and innovation in materials science,” said John Richard, CEO of Americhem. “With the support of PPC, we are expanding our ability to pursue strategic acquisitions that strengthen our technology platform, b
Reply Announces a Partnership With Mistral AI to Develop Sovereign and Enterprise-grade Artificial Intelligence Solutions18.3.2026 09:00:00 CET | Press release
Reply [EXM, STAR: REY] today announced a new partnership agreementwithAI leader Mistral AI aimed at accelerating the adoption of local, customisable, secure and enterprise-grade generative AI solutions at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318232777/en/ Through this collaboration, Reply and Mistral AI provide a trusted and secure environment on European infrastructures, accelerating the adoption of advanced AI solutions while enabling organizations with stringent regulatory, privacy and data protection requirements to fully leverage generative AI. At the core of the collaboration is a shared vision of frontier AI, designed to enable organizations to adopt AI solutions while ensuring data control, protection of sensitive information, compliance with regulatory requirements and deployment on European infrastructures. By combining Mistral AI’s high-performance AI models with Reply’s expertise in designing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom